Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. More Details
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Penumbra's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: PEN's weekly volatility (9%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: PEN exceeded the US Medical Equipment industry which returned 20% over the past year.
Return vs Market: PEN exceeded the US Market which returned 19.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Penumbra's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StShareholders Are Thrilled That The Penumbra (NYSE:PEN) Share Price Increased 247%
5 months ago | Simply Wall StIs Penumbra, Inc.'s (NYSE:PEN) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
6 months ago | Simply Wall StHere's Why We Think Penumbra (NYSE:PEN) Is Well Worth Watching
Is Penumbra undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: PEN ($228.46) is trading above our estimate of fair value ($144.98)
Significantly Below Fair Value: PEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PEN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: PEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PEN is overvalued based on its PB Ratio (13.3x) compared to the US Medical Equipment industry average (5.1x).
How is Penumbra forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: PEN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PEN's is expected to become profitable in the next 3 years.
Revenue vs Market: PEN's revenue (17% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: PEN's revenue (17% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PEN's Return on Equity is forecast to be low in 3 years time (5.4%).
How has Penumbra performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PEN is currently unprofitable.
Growing Profit Margin: PEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PEN is unprofitable, but has reduced losses over the past 5 years at a rate of 28.7% per year.
Accelerating Growth: Unable to compare PEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).
Return on Equity
High ROE: PEN has a negative Return on Equity (-2.03%), as it is currently unprofitable.
How is Penumbra's financial position?
Financial Position Analysis
Short Term Liabilities: PEN's short term assets ($590.2M) exceed its short term liabilities ($108.1M).
Long Term Liabilities: PEN's short term assets ($590.2M) exceed its long term liabilities ($82.5M).
Debt to Equity History and Analysis
Debt Level: PEN is debt free.
Reducing Debt: PEN has not had any debt for past 5 years.
Debt Coverage: PEN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: PEN has no debt, therefore coverage of interest payments is not a concern.
What is Penumbra current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Adam Elsesser (58 yo)
Mr. Adam Elsesser serves as President at Penumbra, Inc. since May 2020. He Co-Founded Penumbra, Inc. in 2004 and has been its Chief Executive Officer since 2004. Mr. Elsesser has been the Chairman since Ja...
CEO Compensation Analysis
Compensation vs Market: Adam's total compensation ($USD726.69K) is below average for companies of similar size in the US market ($USD6.20M).
Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||1.08yrs||US$2.29m||0.017% |
|Executive VP||2.33yrs||US$2.56m||0.11% |
|President of International||6yrs||US$504.29k||1.18% |
|Executive VP & Chief Business Officer||6yrs||US$605.13k||0.34% |
|Vice President of Operations||no data||no data||no data|
|Chief Accounting Officer||1.08yrs||no data||0.028% |
|Chief Technology Officer||no data||no data||no data|
|Chief Scientific Officer||0.50yr||no data||no data|
|Investor Relations Officer||no data||no data||no data|
|Vice President of Quality & Compliance||12yrs||no data||no data|
Experienced Management: PEN's management team is seasoned and experienced (6 years average tenure).
|Independent Director||5.75yrs||US$195.59k||0.034% |
|Independent Director||4yrs||US$179.97k||0.010% |
|Presiding Independent Director||5.42yrs||US$179.97k||0.026% |
|Independent Director||1.5yrs||US$229.90k||0.0014% |
|Independent Director||3.75yrs||US$189.34k||0.0079% |
|Independent Director||2yrs||US$319.93k||0.0040% |
Experienced Board: PEN's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.
Penumbra, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Penumbra, Inc.
- Ticker: PEN
- Exchange: NYSE
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$8.296b
- Shares outstanding: 36.31m
- Website: https://www.penumbrainc.com
Number of Employees
- Penumbra, Inc.
- One Penumbra Place
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PEN||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Sep 2015|
|0P8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2015|
|PEN *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Sep 2015|
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy sys...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/17 00:20|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.